News
-
Arthritis drug could be first to stop heart valve calcification
The first drug to treat calcification of heart valves may be one originally designed for rheumatoid arthritis. Today in Circulation, the journal of the American Heart Association, Vanderbilt University researchers published findings that the drug – a monoclonal antibody known as SYN0012 – shows promise in keeping heart valve leaflets… Read MoreJun. 13, 2017
-
Better models for weather disaster outcomes look beyond historical data
The first drug to treat calcification of heart valves may be one originally designed for rheumatoid arthritis. Today in Circulation, the journal of the American Heart Association, Vanderbilt University researchers published findings that the drug – a monoclonal antibody known as SYN0012 – shows promise in keeping heart valve leaflets… Read MoreJun. 12, 2017
-
Vanderbilt engineering tech uses elephant poachers’ own weapons against them
The first drug to treat calcification of heart valves may be one originally designed for rheumatoid arthritis. Today in Circulation, the journal of the American Heart Association, Vanderbilt University researchers published findings that the drug – a monoclonal antibody known as SYN0012 – shows promise in keeping heart valve leaflets… Read MoreJun. 7, 2017
-
Understanding robotic exosuit-human interaction will boost health and performance
The first drug to treat calcification of heart valves may be one originally designed for rheumatoid arthritis. Today in Circulation, the journal of the American Heart Association, Vanderbilt University researchers published findings that the drug – a monoclonal antibody known as SYN0012 – shows promise in keeping heart valve leaflets… Read MoreJun. 1, 2017
-
fMRI maps electrical activity in brain as precisely as more invasive methods, study finds
The first drug to treat calcification of heart valves may be one originally designed for rheumatoid arthritis. Today in Circulation, the journal of the American Heart Association, Vanderbilt University researchers published findings that the drug – a monoclonal antibody known as SYN0012 – shows promise in keeping heart valve leaflets… Read MoreMay. 31, 2017
-
Interdisciplinary NetsBlox project makes computer programming intuitive
The first drug to treat calcification of heart valves may be one originally designed for rheumatoid arthritis. Today in Circulation, the journal of the American Heart Association, Vanderbilt University researchers published findings that the drug – a monoclonal antibody known as SYN0012 – shows promise in keeping heart valve leaflets… Read MoreMay. 30, 2017
-
BME alumna honored with state STEM advocate award
The first drug to treat calcification of heart valves may be one originally designed for rheumatoid arthritis. Today in Circulation, the journal of the American Heart Association, Vanderbilt University researchers published findings that the drug – a monoclonal antibody known as SYN0012 – shows promise in keeping heart valve leaflets… Read MoreMay. 29, 2017
-
Three postdocs to work with engineering faculty as Academic Pathways Fellows
The first drug to treat calcification of heart valves may be one originally designed for rheumatoid arthritis. Today in Circulation, the journal of the American Heart Association, Vanderbilt University researchers published findings that the drug – a monoclonal antibody known as SYN0012 – shows promise in keeping heart valve leaflets… Read MoreMay. 22, 2017
-
Engineering researchers represent Vanderbilt at D.C. expo of NSF-funded projects
The first drug to treat calcification of heart valves may be one originally designed for rheumatoid arthritis. Today in Circulation, the journal of the American Heart Association, Vanderbilt University researchers published findings that the drug – a monoclonal antibody known as SYN0012 – shows promise in keeping heart valve leaflets… Read MoreMay. 19, 2017
-
Novel nanotube approach earns grad student coveted spot in ORNL innovation program
The first drug to treat calcification of heart valves may be one originally designed for rheumatoid arthritis. Today in Circulation, the journal of the American Heart Association, Vanderbilt University researchers published findings that the drug – a monoclonal antibody known as SYN0012 – shows promise in keeping heart valve leaflets… Read MoreMay. 18, 2017